Abstract
Two molecular phenotypes of the acute respiratory distress syndrome (ARDS) with substantially different clinical trajectories have been identified. Classification as “hyperinflammatory” or “hypoinflammatory” depends on plasma biomarker profiling. Differences in the biology underlying these phenotypes at the site of injury, the lung, are unknown. We analyze tracheal aspirate (TA) transcriptomes from 46 mechanically ventilated subjects to assess differences in lung inflammation and repair between ARDS phenotypes. We then integrate these results with metatranscriptomic sequencing, single-cell RNA sequencing, and plasma proteomics to identify distinct features of each ARDS phenotype. We also compare phenotype-specific differences in gene expression to experimental models of acute lung injury and use an in silico analysis to identify candidate treatments for each phenotype. We find that hyperinflammatory ARDS is associated with increased integrated stress response and interferon gamma signaling, distinct immune cell polarization, and differences in microbial community composition in TA. These findings demonstrate that each phenotype has distinct respiratory tract biology that may be relevant to developing effective therapies for ARDS.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the NIH: F32HL151117 (AS), R35HL140026 (CSC), 2R24AA019661-06A1 (CSC), NIH/NHLBI K23HL138461-01A1 (CRL), U19 AI1077439 (DJE, CSC). Additional funding from: UCSF ImmunoX CoLabs, Chan Zuckerberg Foundation 2019-202665, Genentech TSK-020586
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
These studies were approved by the UCSF Institutional Review Board (17-24056, 20-30497), which granted an initial waiver of informed consent to collect TA and blood samples within 48 hours of ICU admission. Informed consent was then obtained from patients or surrogates.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding: F32HL151117 (AS), R35HL140026 (CSC), 2R24AA019661-06A1 (CSC), NIH/NHLBI K23HL138461-01A1 (CRL), U19 AI1077439 (DJE, CSC), UCSF ImmunoX CoLabs, Chan Zuckerberg Foundation 2019-202665, Genentech TSK-020586
Data Availability
All data produced in the present study are available upon reasonable request to the authors
